M. Scott Harris compensation by year
Altimmune Summary Compensation Table · all 7 fiscal years held| Component | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Salary | $115,032 | $377,092 | $444,385 | $456,000 | $487,569 | $497,952 | $388,403 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $1,000 |
| Stock awards | $0 | $0 | $412,135 | $234,183 | $477,848 | $541,952 | $443,800 |
| Option awards | $171,325 | $92,991 | $1,237,015 | $572,395 | $1,080,331 | $1,228,016 | $1,373,740 |
| Non-equity incentive | $95,318 | $188,700 | $165,680 | $182,400 | $191,520 | $189,222 | $204,559 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $1,233 | $11,400 | $4,046 | $4,640 | $2,720 | $3,563 | $219,569 |
| Total | $382,908 | $670,183 | $2,263,260 | $1,449,618 | $2,239,988 | $2,460,705 | $2,631,071 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Altimmune, Inc. DEF 14A filed March 17, 2026, accession 0001104659-26-028953, and prior-year filings.
How this page was built: the Altimmune, Inc. filed document, accession 0001104659-26-028953. Every figure is read from that document and cited to the page and table it appears in. Filed March 17, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 63,400 | $228,874 | — |
| RSU | 43,800 | $158,118 | — |
| RSU | 18,550 | $66,966 | — |
| RSU | 7,775 | $28,068 | — |
| Option | 85,000 | — | $9.28 |
| Option | 183,600 | — | $7.00 |
| Option | 3,816 | — | $7.53 |
| Option | 28,438 | — | $12.88 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Altimmune, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Altimmune’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Vipin Garg | Chief Executive Officer | $8,026,590 |
| M. Scott Harris · this page | former Chief Medical Officer | $2,631,071 |
| Christophe Arbet-Engels | Chief Medical Officer | $2,329,895 |
| M. Scot Roberts | Chief Scientific Officer | $2,182,996 |
M. Scott Harris's compensation dossier, Altimmune
You have read M. Scott Harris's totals and holdings. The dossier adds each equity grant Altimmune disclosed for M. Scott Harris and Altimmune's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Altimmune compensation record
free company briefThis page is one person within Altimmune's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Altimmune proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Altimmune's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Altimmune's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.